ERBB2 and breast cancer: Further, we were not able to evaluate SMRs by breast cancer subtype (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status) or by hormone therapy use since these data were not available consistently throughout our follow-up.